Shots:

• The companies reported the new data from the LANDSCAPE clinical program including (SHORELINE) & (WATERFALL) studies evaluates zuranolone in patients with MDD
• In the (WATERFALL) study, the therapy showed improvements in depressive & anxiety symptoms as early as the first measured time point (Day 3 for HAMD-17 & Day 8 for HAM-A), rapid onset of effect in HAMD-17 was observed over PBO as early as Day 3, safety data were consistent with the safety profile across the LANDSCAPE program
• In the (SHORELINE) Study, the therapy showed similar efficacy & safety results in the datasets analyzed to that observed in a general study population, was well-tolerated in a subgroup of patients aged ≥65yrs.

 Ref: Businesswire | Image: Biogen